NZ555571A - Alpha thymosin peptides as cancer vaccine adjuvants - Google Patents
Alpha thymosin peptides as cancer vaccine adjuvantsInfo
- Publication number
- NZ555571A NZ555571A NZ555571A NZ55557105A NZ555571A NZ 555571 A NZ555571 A NZ 555571A NZ 555571 A NZ555571 A NZ 555571A NZ 55557105 A NZ55557105 A NZ 55557105A NZ 555571 A NZ555571 A NZ 555571A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- vaccine
- cells
- subject
- tumor
- Prior art date
Links
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 40
- 238000009566 cancer vaccine Methods 0.000 title claims abstract description 36
- 229940022399 cancer vaccine Drugs 0.000 title claims abstract description 36
- 102000007501 Thymosin Human genes 0.000 title description 5
- 239000012646 vaccine adjuvant Substances 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 155
- 201000011510 cancer Diseases 0.000 claims abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 230000000899 immune system response Effects 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 75
- 108010078233 Thymalfasin Proteins 0.000 claims description 58
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 58
- 229960004231 thymalfasin Drugs 0.000 claims description 58
- 230000004044 response Effects 0.000 claims description 31
- 230000028993 immune response Effects 0.000 claims description 30
- 230000003053 immunization Effects 0.000 claims description 23
- 238000002649 immunization Methods 0.000 claims description 22
- 210000004698 lymphocyte Anatomy 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 17
- 230000004083 survival effect Effects 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000021039 metastatic melanoma Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000008732 thymoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 99
- 108091007433 antigens Proteins 0.000 description 77
- 102000036639 antigens Human genes 0.000 description 77
- 239000000427 antigen Substances 0.000 description 76
- 210000004881 tumor cell Anatomy 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 29
- 210000000987 immune system Anatomy 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 230000007246 mechanism Effects 0.000 description 16
- 210000000822 natural killer cell Anatomy 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- 239000012636 effector Substances 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 238000001994 activation Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- KHGNFPUMBJSZSM-UHFFFAOYSA-N 8-(3-hydroxy-3-methylbutyl)-4,8-dimethoxy-6,7-dihydro-5h-furo[2,3-b]quinolin-7-ol Chemical compound COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000035269 cancer or benign tumor Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000037451 immune surveillance Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000002914 neoplasic effect Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000013188 needle biopsy Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 108700016958 thymosin fraction 5 Proteins 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- -1 CD 34 Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 102100031037 Complement component C9 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010027454 Metastases to breast Diseases 0.000 description 1
- 206010027462 Metastases to ovary Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63317504P | 2004-12-06 | 2004-12-06 | |
| PCT/US2005/043985 WO2006062917A2 (en) | 2004-12-06 | 2005-12-06 | Alpha thymosin peptides as cancer vaccine adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ555571A true NZ555571A (en) | 2009-02-28 |
Family
ID=36578462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ555571A NZ555571A (en) | 2004-12-06 | 2005-12-06 | Alpha thymosin peptides as cancer vaccine adjuvants |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100092499A1 (de) |
| EP (1) | EP1835931A4 (de) |
| JP (1) | JP2008523067A (de) |
| KR (1) | KR20070086663A (de) |
| CN (1) | CN101072582B (de) |
| AU (1) | AU2005314271B2 (de) |
| BR (1) | BRPI0518571A2 (de) |
| CA (1) | CA2588685A1 (de) |
| EA (1) | EA015510B1 (de) |
| IL (1) | IL183264A (de) |
| MX (1) | MX2007006717A (de) |
| NO (1) | NO20072705L (de) |
| NZ (1) | NZ555571A (de) |
| UA (1) | UA90493C2 (de) |
| WO (1) | WO2006062917A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009079338A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa) |
| WO2010129947A2 (en) * | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| CA2826875A1 (en) * | 2011-02-09 | 2012-08-16 | Sciclone Pharmaceuticals, Inc. | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
| CN104136040B (zh) * | 2012-01-20 | 2021-05-25 | 费尔南多·托姆·克罗伊茨 | 自体癌细胞疫苗 |
| CN104507491A (zh) * | 2012-03-08 | 2015-04-08 | 赛生制药有限公司 | 胸腺素α在治疗化脓性鼻窦炎中的应用 |
| TWI749433B (zh) * | 2014-10-21 | 2021-12-11 | 開曼群島商賽生製藥國際有限公司 | 用免疫刺激物治療癌症 |
| CN107281476B (zh) * | 2017-04-06 | 2020-11-24 | 中国医科大学 | 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用 |
| RU2645957C1 (ru) * | 2017-04-10 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения лучевых повреждений мочевого пузыря |
| RU2663468C1 (ru) * | 2017-09-25 | 2018-08-06 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US653758A (en) * | 1900-03-20 | 1900-07-17 | Austin Gale | Hay-stacking device. |
| DE2604845A1 (de) | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| JPH0420624A (ja) * | 1990-02-06 | 1992-01-24 | Kanji Yokoe | 勾配側溝施工法及び当該工法に使用する可変側溝 |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| JP2004500029A (ja) * | 1999-06-30 | 2004-01-08 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
| MXPA04003864A (es) * | 2001-10-26 | 2004-08-11 | Immuno Rx Inc | Inmunoterapia para revertir la supresion inmune. |
| DK1448223T3 (da) * | 2001-10-26 | 2008-02-18 | Rhode Island Hospital | Thymosin-forögelse af genetisk immunisering |
| WO2004003174A2 (en) * | 2002-06-28 | 2004-01-08 | Sciclone Pharmaceuticals Inc. | Method of up-regulating tumor antigen expression using thymalfasin |
| UA80870C2 (en) * | 2003-03-28 | 2007-11-12 | Sciclone Pharmaceuticals Inc | Method for treatment or prevention of aspergillus infections with thymosin alpha 1 |
| EP2633866A3 (de) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Kombinationstherapie |
| WO2010129947A2 (en) * | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
-
2005
- 2005-12-06 CA CA002588685A patent/CA2588685A1/en not_active Abandoned
- 2005-12-06 MX MX2007006717A patent/MX2007006717A/es active IP Right Grant
- 2005-12-06 NZ NZ555571A patent/NZ555571A/en not_active IP Right Cessation
- 2005-12-06 KR KR1020077014527A patent/KR20070086663A/ko not_active Application Discontinuation
- 2005-12-06 JP JP2007545547A patent/JP2008523067A/ja active Pending
- 2005-12-06 US US11/720,909 patent/US20100092499A1/en not_active Abandoned
- 2005-12-06 CN CN2005800417998A patent/CN101072582B/zh active Active
- 2005-12-06 BR BRPI0518571-8A patent/BRPI0518571A2/pt not_active IP Right Cessation
- 2005-12-06 EA EA200701166A patent/EA015510B1/ru not_active IP Right Cessation
- 2005-12-06 WO PCT/US2005/043985 patent/WO2006062917A2/en active Application Filing
- 2005-12-06 UA UAA200707406A patent/UA90493C2/ru unknown
- 2005-12-06 AU AU2005314271A patent/AU2005314271B2/en not_active Ceased
- 2005-12-06 EP EP05853022A patent/EP1835931A4/de not_active Withdrawn
-
2007
- 2007-05-16 IL IL183264A patent/IL183264A/en not_active IP Right Cessation
- 2007-05-29 NO NO20072705A patent/NO20072705L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101072582A (zh) | 2007-11-14 |
| JP2008523067A (ja) | 2008-07-03 |
| AU2005314271B2 (en) | 2011-06-16 |
| MX2007006717A (es) | 2007-08-06 |
| NO20072705L (no) | 2007-09-05 |
| CA2588685A1 (en) | 2006-06-15 |
| WO2006062917A2 (en) | 2006-06-15 |
| US20100092499A1 (en) | 2010-04-15 |
| UA90493C2 (ru) | 2010-05-11 |
| AU2005314271A1 (en) | 2006-06-15 |
| IL183264A0 (en) | 2007-09-20 |
| CN101072582B (zh) | 2012-06-27 |
| EP1835931A2 (de) | 2007-09-26 |
| EA015510B1 (ru) | 2011-08-30 |
| EA200701166A1 (ru) | 2008-02-28 |
| WO2006062917A3 (en) | 2006-11-16 |
| BRPI0518571A2 (pt) | 2008-11-25 |
| IL183264A (en) | 2010-12-30 |
| KR20070086663A (ko) | 2007-08-27 |
| EP1835931A4 (de) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005314271B2 (en) | Alpha thymosin peptides as cancer vaccine adjuvants | |
| Hadden | Immunodeficiency and cancer: prospects for correction | |
| CA2717854C (en) | Allogeneic cancer cell-based immunotherapy | |
| CN107488235B (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| WO2014161887A1 (en) | Targeted cancer immune therapy | |
| US20140072596A1 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| WO2018137643A1 (zh) | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 | |
| JP5227028B2 (ja) | インターロイキン−２の中和能を有する免疫治療用製剤 | |
| RU2192274C2 (ru) | Иммуногенная композиция на основе tlp | |
| JP2002502880A (ja) | ハプテン改変化腫瘍細胞膜およびその使用 | |
| Das et al. | Immunotherapeutic treatment strategies for primary brain tumors | |
| US20090060946A1 (en) | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells | |
| US20230355678A1 (en) | Methods for improving t cell efficacy | |
| WO2004096244A1 (en) | Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same | |
| KR100522526B1 (ko) | 면역 치료용 수지상 세포의 제조방법 | |
| Salem et al. | Tumours: Immunotherapy | |
| McKechnie et al. | Vaccination and malignant disease: Promising therapeutic approach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: SCICLONE PHARMACEUTICALS, US Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC. |
|
| ASS | Change of ownership |
Owner name: SCICLONE PHARMACEUTICALS, US Free format text: OLD OWNER(S): SCICLONE PHARMACEUTICALS, INC. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |